- Home
- RAMP vs AKRO Comparison
RAMP vs AKRO Comparison
Compare RAMP & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- AKRO
- Stock Information
- Founded
- RAMP 2018
- AKRO 2017
- Country
- RAMP United States
- AKRO United States
- Employees
- RAMP N/A
- AKRO N/A
- Industry
- RAMP EDP Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- AKRO Health Care
- Exchange
- RAMP Nasdaq
- AKRO Nasdaq
- Market Cap
- RAMP 1.6B
- AKRO 2.1B
- IPO Year
- RAMP 1987
- AKRO 2019
- Fundamental
- Price
- RAMP $25.35
- AKRO $31.59
- Analyst Decision
- RAMP Buy
- AKRO Strong Buy
- Analyst Count
- RAMP 6
- AKRO 7
- Target Price
- RAMP $41.83
- AKRO $43.20
- AVG Volume (30 Days)
- RAMP 516.6K
- AKRO 441.5K
- Earning Date
- RAMP 11-06-2024
- AKRO 11-11-2024
- Dividend Yield
- RAMP N/A
- AKRO N/A
- EPS Growth
- RAMP N/A
- AKRO N/A
- EPS
- RAMP 0.09
- AKRO N/A
- Revenue
- RAMP $681,553,000.00
- AKRO N/A
- Revenue This Year
- RAMP $12.24
- AKRO N/A
- Revenue Next Year
- RAMP $8.67
- AKRO N/A
- P/E Ratio
- RAMP $283.08
- AKRO N/A
- Revenue Growth
- RAMP 12.02
- AKRO N/A
- 52 Week Low
- RAMP $21.45
- AKRO $11.36
- 52 Week High
- RAMP $42.66
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- RAMP 55.43
- AKRO 66.34
- Support Level
- RAMP $24.07
- AKRO $29.34
- Resistance Level
- RAMP $25.22
- AKRO $32.15
- Average True Range (ATR)
- RAMP 0.49
- AKRO 1.26
- MACD
- RAMP 0.12
- AKRO 0.10
- Stochastic Oscillator
- RAMP 97.58
- AKRO 99.74
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.